Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44).

Abstract

1006 Background: The addition of bevacizumab (Bev) to EC-docetaxel chemotherapy (CT) did not improve pathological complete response (pCR) rates in unselected patients (P) with HER2 negative breast cancers (von Minckwitz G et al, San Antonio 2010). Secondary aim of GeparQuinto was to determine pCR rates in patients with triple-negative breast cancer (TNBC) exclusively. Methods: P with untreated TNBC (ER and PgR <10% and HER2 IHC score 0/1 or FISH negative; detected locally) were included in GeparQuinto if they had T1c-T4d tumors and showed no increased cardiac or bleeding risks. P were randomized to receive 4 cycles EC (90/600 mg/m²) q3w followed by 4 cycles docetaxel (100mg/m²) with or without Bev 15mg/kg q3w added to CT cycles. P not clinically responding to EC ± Bev were considered as treatment failures and entered another part of the protocol. P were a stratified subset of the 1948 participants of the HER2 negative part of GeparQuinto. Results: In total 684 P with TNBC were randomized to EC-D (N=345) a...